wsj.com

WSJ coverage of investment activity in psychedelic drugs, focusing on market and funding implications for psychedelic pharma. The page is not accessible from this environment due to a restricted URL fetch, so specific company names, investment amounts, timeline, and key claims cannot be verified here. If you paste the visible text or key excerpts (headline, subhead, and first 2-3 paragraphs), I can extract an accurate subject-level summary and identify any explicitly named substances.